An observational study in Diabetes Mellitus, sponsored by Medical University of Graz. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Medical University of Graz · Observational
Identification of risks of the GlucoTab system in routine use.
A study to identify risks in routine use of the GlucoTab system for glycaemic management in non-critically ill patients with type 2 diabetes at general wards.
Medical University of Graz is the lead sponsor of 459 studies on the registry; 98 are open to participants now.
Counted across the registry records on this site, refreshed daily.
non-critically ill patients with type 2 diabetes at general wards
Exclusion Criteria:
Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week
efficacy: mean daily blood glucose during hospital stay, an expected average of 1 week
Time frame: participants will be followed for the duration of hospital stay, an expected average of 1 week
Efficacy: Blood Glucose During Hospital Stay
Efficacy: mean pre-breakfast blood glucose during hospital stay
Time frame: participants will be followed for the duration of hospital stay, an expected average of 1 week
Usability: Coverage of the GlucoTab
Usability: coverage of the GlucoTab treatment during hospital stay
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 week
| Milestone | Intervention |
|---|---|
| Started | 150 |
| Completed | 150 |
| Not completed | 0 |
efficacy: mean daily blood glucose during hospital stay, an expected average of 1 week
| mg/dl | Intervention |
|---|---|
| Efficacy: Blood Glucose During Hospital Stay, an Expected Average of 1 Week | 159 ± 32 |
Efficacy: mean pre-breakfast blood glucose during hospital stay
| mg/dl | Intervention |
|---|---|
| Efficacy: Blood Glucose During Hospital Stay | 147 ± 38 |
Usability: coverage of the GlucoTab treatment during hospital stay
| percentage of hospital stay | Intervention |
|---|---|
| Usability: Coverage of the GlucoTab | 71.4 ± 23.4 |
Collected over during hospital stay. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention | — | 1/150 (0.7%) | 3/150 (2%) |
| Event | Intervention |
|---|---|
| Pneumonia and cardiac decompensation requiring treatment in intensive care unitCardiac disorders | 1/150 |
| Event | Intervention |
|---|---|
| CystitisInfections and infestations | 3/150 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/150 |
| AV Block Grad 3Cardiac disorders | 1/150 |
| Haemorrhagic GastritisGastrointestinal disorders | 1/150 |
| Antibiotic associated exanthemaSkin and subcutaneous tissue disorders | 1/150 |
| Insult (Posteriorinfarction after intracardiac catheter)Vascular disorders | 1/150 |
| Autoimmune hemolytic anemiaBlood and lymphatic system disorders | 1/150 |
| CholecystolithiasisHepatobiliary disorders | 1/150 |
| Aneurysma spurium right groinVascular disorders | 1/150 |
| NSTEMICardiac disorders | 1/150 |
| Age, Continuous(years) | Intervention |
|---|---|
| Mean | 68 ± 11 |
| Sex: Female, Male(Participants) | Intervention |
|---|---|
| Female | 56 |
| Male | 94 |
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Graz